Doc, we're in agreement. I believe that there is a misconception about research sites such as UCLA, City of Hope, etc becoming drugmakers, I don't believe that will ever happen. These research sites develop a tremendous number of great products, but they don't attempt to fund them through pivotal trials, which often go into hundreds of millions, or billions of dollars. Rather they license to biotech's or BP's for nice royalty streams. I'm hoping that the existing relationship between NWBO and UCLA results in such actions. That doesn't prevent the BP's from coming along later to partner, or attempt to acquire the technology, but at a dramatically higher price.
I believe that NWBO has taken the vaccine so far that it is too late for a BP to acquire it, NWBO is positioned to become a giant among the Biotech's, as AMGN did decades ago. It's not that the BP's are out in the cold, they're positioned to partner with NWBO, taking a substantial equity position, and providing the funding needed for NWBO's growth. One or more BP will make big profits by being NWBO's partner as the value of their stock position grows dramatically, it's also very possible they perform certain tasks for the company which they'll be paid for.
As for us stockholders, we'll be well rewarded by partnerships as they'll always be made at a substantial premium to the current stock price, the stock will then trade at, or near the price being paid in the partnership.
Gary
Bullish
AI
Market Data 
Markets 
